Lupus Anticoagulant is the Strongest Risk Factor for both Venous and Arterial Thrombosis in Patients with Systemic Lupus Erythematosus

Summary

Antiphospholipid antibodies (aPL) characterize patients at risk for both arterial and venous thrombotic complications. Recently it has been recognized that the presence of plasma proteins such as β₂-glycoprotein I (β2GPI) and prothrombin are essential for the binding of aPL to phospholipids and that these proteins are probably the real target of aPL. The discovery of these new antigens for aPL introduces the possibility of new assays to detect the presence of aPL. However, it is not known whether these assays improve the identification of patients at risk for thrombosis.

In this retrospective study we compared the value of the classic assays LAC (lupus anticoagulant) and ACA (anticardiolipin antibodies) to detect aPL associated with thrombotic complications, with new assays which are based on the binding of aPL to the plasma proteins prothrombin and P2GPI. To do so, we have used these assays in a group of 175 SLE patients and correlated the positivity of the different assays with the presence of a history of venous and arterial thrombosis. Control groups were patients without SLE but with LAC and/or ACA and thrombosis (n = 23), patients with thrombosis without LAC and ACA (n = 40) and 42 healthy controls.

In the univariate analysis, in which no distinction has been made between high and low antibody levels, we confirmed LAC and ACA to be related to both arterial and venous thrombosis. Anti-β2GPI- and anti-prothrombin-antibodies, both IgG and IgM correlate with venous thrombosis and anti-β2GPI-IgM with arterial thrombosis. Multivariate analysis showed that LAC is the strongest risk factor (OR 9.77; 95% CI 1.74-31.15) for arterial thrombosis. None of the other factors is a significant additional risk factor. For venous thrombosis LAC is the strongest risk factor (OR 6.55; 95% Cl 2.36-18.17), but ACA-IgM above 20 MPL units also appeared to be a significant (p = 0.0159) risk factor (OR 3.90; 95% Cl 1.29-11.80). Furthermore, the presence of anti-β2GPI- and/or anti-prothrombin-antibodies in LAC positive patients (n = 60) does not increase the risk for thrombosis.

The results showed that (i) the LAC assay correlates best with a history of both arterial and venous thrombosis and (ii) neither the anti-P2GPI ELISA nor the anti-prothrombin ELISA gives additional information for a thrombotic risk in SLE patients.

• References

• 1 Love PE, Santoro SA. Antiphospholipid antibodies: anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders. Prevalence and clinical significance. Ann Intern Med 1990; 112: 682-698
• 2 Harris EN, Asherson RA, Hughes GR. Antiphospholipid antibodies-auto-antibodies with a difference. Annu Rev Med 1988; 39: 261-271
• 3 de Groot PG, Oosting JD, Derksen RHWM. Antiphospholipid antibodies: specificity and pathophysiology. Bailliere’s Clin Haematol 1993; 6: 691-709
• 4 Roubey RAS. Autoantibodies to phospholipid-binding plasma proteins: A new view of lupus anticoagulants and other “antiphospholipid” autoantibodies. Blood 1994; 84: 2854-2867
• 5 Galli M, Comfurius P, Maassen C, Hemker HC, de Baets MH, van Breda-Vriesman PJC, Barbui T, Zwaal RFA, Bevers EM. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein factor. Lancet 1990; 335: 1544-1547
• 6 McNeil HP, Simpson RJ, Chesterman CN, Krilis SA. Antiphospholipid antibodies are directed against a complex antigen that includes a lipid binding inhibitor of coagulation: β₂-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci USA 1990; 87: 4120-4124
• 7 Oosting JD, Derksen RHWM, Entjes HTI, Bouma BN, de Groot PG. Lupus anticoagulant activity is frequently dependent on the presence of β₂-glycoprotein I. Thromb Haemost 1992; 67: 499-502
• 8 Bevers EM, Galli M, Barbui T, Comfurius P, Zwaal RFA. Lupus anticoagulant IgG’s (LA) are not directed to phospholipids only, but to a complex of lipid-bound human prothrombin. Thromb Haemost 1991; 66: 629-632
• 9 Permpikul P, Rao LVM, Rapaport SI. Functional and binding studies of the roles of prothrombin and β₂-glycoprotein I in the expression of lupus anticoagulant activity. Blood 1994; 83: 2878-2892
• 10 El-Kadi HS, Keil LB, De Bari V. Analytical and clinical relationships between human IgG autoantibodies to β₂-glycoprotein and anticardiolipin antibodies. J Rheumatol 1995; 22: 2233-2237
• 11 Kaburaki J, Kuwana M, Ikeda Y, Yamamoto M, Kawai S, Matsuura E. Cofactor β₂-glycoprotein I) dependent anticardiolipin antibodies and thrombosis [letter]. J Rheumatol 1994; 21: 1371-1372
• 12 Martinuzzo ME, Forastiero RR, Carreras LO. Anti β₂-glycoprotein I antibodies: Detection and association with thrombosis. Br J Haematol 1995; 89: 397-402
• 13 McNally T, Purdy G, Mackie IJ, Machin SJ, Isenberg DA. The use of an anti-β₂-glycoprotein I assay for discrimination between anticardiolipin antibodies associated with infection and increased risk of thrombosis. Br J Haematol 1995; 91: 471-473
• 14 Weiss L, You JF, Giral P, Alhenc-Gelas M, Senger D, Kazatchkine MD. Anti-cardiolipin antibodies are associated with anti-endothelial cell antibodies but not with anti-β₂-glycoprotein I antibodies in HIV infection. Clin Immunol Immunopathol 1995; 77: 69-74
• 15 Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, Schal-ler JG, Talal N, Winchester RJ. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271-1277
• 16 Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI. A disease activity index for lupus patients. Arthritis Rheum 1992; 35: 630-640
• 17 Oosting JD, Derksen RHWM, Hackeng TM, Van Vliet M, Preissner KT, Bouma BN, de Groot PG. In vitro studies of antiphospholipid antibodies and its cofactor, β₂-glycoprotein I, show negligible effects on endothelial cell mediated protein C activation. Thromb Haemost 1991; 66: 666-671
• 18 Haupt H, Schwick HG, Storiko K. (On a hereditary β₂-glycoprotein I deficiency). Uber einen erblichen β₂-Glykoprotein I-Mangel. Humangenetik 1968; 5: 291-293
• 19 Fujikawa K, Thompson AR, Legaz ME, Meyer RG, Davie EW. Isolation and characterization of bovine factor IX (Christmas factor). Biochemistry 1973; 12: 4938-4945
• 20 Amout J, Vanrusselt M, Huybrechts E, Vermylen J. Optimization of the dilute prothrombin time for the detection of the lupus anticoagulant by use of a recombinant tissue thromboplastin. Br J Haematol 1994; 87: 94-99
• 21 Derksen RH, Hasselaar P, Blokzijl L, Gmelig Meyling FH, de Groot PG. Coagulation screen is more specific than the anticardiolipin antibody ELISA in defining a thrombotic subset of lupus patients. Ann Rheum Dis 1988; 47: 364-371
• 22 Comfurius P, Bevers EM, Galli M, Zwaal RF. Regulation of phospholipid asymmetry and induction of antiphospholipid antibodies. Lupus 1995; 4 (Suppl. 01) S19-S22
• 23 Tax WJM, Kramers C, Van Bruggen MCJ, Berden JHM. Apoptosis, nu-cleosomes, and nephritis in systemic lupus erythematosus. Kidney Int 1995; 48: 666-673
• 24 Viard JP, Amoura Z, Bach JF. Association of anti-β₂ glycoprotein I antibodies with lupus-type circulating anticoagulant and thrombosis in systemic lupus erythematosus (see comments). Am J Med 1992; 93: 181-186
• 25 Ginsberg JS, Wells PS, Brill-Edwards P, Donovan D, Moffatt K, Johnston M, Stevens P, Hirsh J. Antiphospholipid antibodies and venous thromboembolism. Blood 1995; 86: 3685-3691